

Outcomes of non-Hodgkin lymphoma patients receiving transplantations from related vs. unrelated donors

Allogeneic hematopoietic cell transplantation or donor transplants can be curative for those with high-risk blood cancers including non-Hodgkin lymphoma. For patients lacking an immunologically (HLA) matched sibling donor, alternative donor sources include HLA-matched unrelated donors and HLA-mismatched related donors. The authors analyzed outcomes of 248 adult recipients of matched unrelated and mismatched related donor transplants for non-Hodgkin lymphoma after lower intensity conditioning, reported to the Center for International Blood and Marrow Transplant Research from 1997 to 2004. Treatment-related mortality at 100 days was 24%. Three-year overall survival and progression-free survival were 41% and 32%, respectively. For selected patients with non-Hodgkin lymphoma, lack of an available sibling donor should not be a barrier to allogeneic hematopoietic cell transplantation.

Source: Alternate donor hematopoietic cell transplantation (HCT) in non-Hodgkin lymphoma using lower intensity conditioning: a report from the CIBMTR. Hale GA, Shrestha S, Le-Rademacher J, Burns LJ, Gibson J, Inwards DJ, Freytes CO, Bolwell BJ, Hsu JW, Slavin S, Isola L, Rizzieri DA, Gale RP, Laport GG, Montoto S, Lazarus HM, Hari PN. *Biology of Blood and Marrow Transplantation*. Epub 2011 Dec 07.